Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GENELUX CORP
GNLX | US
2.77
USD-0.07
-2.46%
GNLX | US
About GENELUX CORP
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
2.77
Open
2.85
High
2.85
Low
2.73
Genelux Corporation a clinical-stage biopharmaceutical company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 an animal health product candidate. It has a licensing agreement with ELIAS Animal Health LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village California.
View LessGNLX | US
Risk
71.6
Sharpe
0.10
Luna's Score
45/100
Recommendation
Sell
Luna says (GNLX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
60.9%1 month
71.6%3 months
64.6%6 months
96.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.52
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
-327.19
Ent. to rev.
7.94K
PEG
-
Other Fundamentals
EBITDA
-26.96M
MarketCap
95.66M
MarketCap(USD)
95.66M
Div. yield
-
Op. margin
-341.44K
Erngs. growth
-
Rev. growth
-95.30
Ret. on equity
-88.57
Short ratio
5.72
Short perc.
3.84
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.59
Range1M
0.60
Range3M
0.78
Volumes: Market Activity
Rel. volume
0.24
Price X volume
162.31K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -327.19 | - | Cheaper |
| Ent. to Revenue | 7,942.94 | - | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.52 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 64.57 | - | Par |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 95.66M | - | Emerging |
